The UK and US have signed a major bilateral deal that will maintain no duties on UK pharmaceutical products entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the NHS. This pledge guarantees that tariffs on these crucial exports will be held at zero for a duration of 36 months.
This deal is in response to earlier warnings to hike duties on patented drug imports, with potential rates mentioned reaching 100%.
"This arrangement with the UK strengthens the international landscape for new treatments and brings long-overdue balance to transatlantic pharmaceutical trade," an announcement declared.
Trade Importance
Medicines are one of the Britain's biggest export categories to the United States, which is by far the primary market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to September, the UK shipped drugs totaling over eleven billion pounds to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This deal secures employment, increases investment and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The agreement entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to double total NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be capped at 15%. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by assertions that American consumers were paying a premium for the equivalent treatments than consumers in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been announced toward projects in the United States.
One official publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a share of its total funding over the previous ten-year period.
